Cardiovascular morbidity and CABG surgery--a perspective: epidemiology, costs, and potential therapeutic solutions

D T Mangano1

  • 1McSPI Research Group, University of California, San Francisco, USA.

Insights

Cardiovascular disease remains a leading cause of death, with significant perioperative complications impacting patients undergoing bypass surgery. Research into cost-effective therapies is crucial for improving patient outcomes and healthcare resource management.

Area of Science:

  • Cardiology
  • Perioperative Medicine
  • Health Economics

Background:

  • Cardiovascular disease (CVD) is the primary cause of mortality globally, exacerbated by an aging population and demographic shifts.
  • Perioperative cardiac complications, including death, myocardial infarction, and heart failure, affect at least 10% of patients undergoing coronary artery bypass graft (CABG) surgery.
  • These complications incur substantial healthcare costs, estimated at $2 billion annually in the United States alone.

Purpose of the Study:

  • To highlight the persistent challenges in managing cardiovascular disease despite advancements.
  • To underscore the significant burden of perioperative cardiac complications in CABG patients.
  • To emphasize the need for research into cost-effective therapeutic strategies.

Main Methods:

  • Review of existing literature on cardiovascular disease management and perioperative outcomes.
  • Analysis of healthcare resource utilization related to cardiac complications.
  • Examination of the impact of cost-saving healthcare policies on cardiovascular patient care.

Main Results:

  • Cardiovascular disease continues to be a major global health concern.
  • Perioperative cardiac complications represent a significant clinical and economic challenge in cardiac surgery.
  • Current healthcare cost-saving measures may impact the quality of care for cardiovascular patients.

Conclusions:

  • Despite advances, cardiovascular disease management requires ongoing attention due to demographic changes.
  • Addressing perioperative cardiac complications is essential for improving patient survival and reducing healthcare expenditures.
  • Further research and clinical studies are vital for developing effective and economical therapeutic approaches for cardiovascular patients.

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...